Branded Rx · FDA-approved

Ozempic®

FDA-approved semaglutide. The path your insurance is most likely to cover.

Ozempic is the FDA-approved branded version of semaglutide, manufactured by Novo Nordisk and indicated for type 2 diabetes (with weight management as a documented effect). At Cypress, you pay up front and submit to your insurance for reimbursement — we coordinate the prescription, you handle the claim.

  • FDA-approved — manufactured by Novo Nordisk
  • Once-weekly subcutaneous injection
  • Pay up front, submit to your insurance for reimbursement
  • Includes clinician oversight and pharmacy coordination
  • Insurance reimbursement varies by plan — we don't bill insurance
Start your assessment

Why branded

Branded GLP-1 has its place.

Woman in midlife considering her care options

Branded Ozempic is FDA-approved, manufactured under the strictest regulatory standards, and the version many insurance plans are most familiar with for prior authorization and reimbursement.

If you have insurance coverage that may reimburse for branded GLP-1, this path can be the right financial choice — even though you pay full cost up front. Your clinician will help you think through whether branded Ozempic, branded Wegovy (the obesity-indicated semaglutide brand), or compounded options fit your situation.

Cypress is not affiliated with Novo Nordisk. Ozempic is a registered trademark of its respective owner.

How Cypress branded works

What we do, and what we don't.

1
We prescribe and coordinate
Your clinician evaluates whether branded GLP-1 is appropriate, prescribes it, and coordinates with a pharmacy to fulfill.
2
You pay up front
You pay the full cost at fulfillment. We confirm the price with you before any charge so there are no surprises.
3
You file the claim
We provide all documentation needed for your insurance claim. You submit to your plan and they reimburse you directly. We do not bill insurance.

Side effects & safety

What to know before you start.

Woman reviewing health information at home

Most common: nausea, decreased appetite, mild diarrhea, constipation, fatigue. Typically dose-related.

Less common but important: pancreatitis, gallbladder issues, low blood sugar (especially with insulin/sulfonylureas).

Not appropriate if: personal/family history of medullary thyroid carcinoma or MEN2; pregnant, planning pregnancy, or breastfeeding; severe GI or end-stage organ disease.

The branded path. Start today.

The 3-minute medical screener is free. We'll ask about your insurance early so we can advise on the right path.

Start your assessment